• Explore /
  • Poster
  • / A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36).

A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36).

Abstract Video & Slides Poster

Authors

null

Giuseppe Procopio

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Giuseppe Procopio , Chiara Pircher , Melanie Claps , Valentina Guadalupi , Alessia Mennitto , Pierangela Sepe , Francesca Corti , Ugo De Giorgi , Cristian Lolli , Umberto Basso , Marco Maruzzo , Davide Bimbatti , Elena Verri , Franco Nole , Sandro Pignata , Filippo G. De Braud , Elena Verzoni

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03463681

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 326)

DOI

10.1200/JCO.2021.39.6_suppl.326

Abstract #

326

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Giuseppe Procopio

First Author: Elena Verzoni

First Author: Geoffrey Thomas Gibney

First Author: Paul L. de Souza